Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
$82.29
-2.6%
$83.66
$28.06
$103.00
$6.77B2.06676,685 shs242,608 shs
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
$103.82
-6.8%
$95.18
$42.89
$114.99
$6.35B0.52912,739 shs663,540 shs
Qiagen N.V. stock logo
QGEN
Qiagen
$33.02
-0.8%
$39.36
$32.53
$57.81
$6.80B0.642.33 million shs1.12 million shs
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
$37.35
-1.6%
$32.97
$7.73
$42.27
$1.78B0.82340,738 shs113,027 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
-1.27%-0.15%-5.98%+2.62%+184.03%
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
+2.04%+8.22%+14.95%+8.04%+150.93%
Qiagen N.V. stock logo
QGEN
Qiagen
+1.74%-0.58%-20.23%-33.98%-23.26%
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
-0.34%-4.96%+4.98%+35.88%+294.08%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
$82.29
-2.6%
$83.66
$28.06
$103.00
$6.77B2.06676,685 shs242,608 shs
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
$103.82
-6.8%
$95.18
$42.89
$114.99
$6.35B0.52912,739 shs663,540 shs
Qiagen N.V. stock logo
QGEN
Qiagen
$33.02
-0.8%
$39.36
$32.53
$57.81
$6.80B0.642.33 million shs1.12 million shs
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
$37.35
-1.6%
$32.97
$7.73
$42.27
$1.78B0.82340,738 shs113,027 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
-1.27%-0.15%-5.98%+2.62%+184.03%
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
+2.04%+8.22%+14.95%+8.04%+150.93%
Qiagen N.V. stock logo
QGEN
Qiagen
+1.74%-0.58%-20.23%-33.98%-23.26%
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
-0.34%-4.96%+4.98%+35.88%+294.08%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
2.96
Moderate Buy$118.1043.52% Upside
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
2.93
Moderate Buy$136.4231.39% Upside
Qiagen N.V. stock logo
QGEN
Qiagen
2.50
Moderate Buy$46.3840.45% Upside
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
3.00
Buy$54.8346.79% Upside

Current Analyst Ratings Breakdown

Latest RAPP, QGEN, KYMR, and MIRM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/12/2026
Qiagen N.V. stock logo
QGEN
Qiagen
DowngradeHold (C)Hold (C-)
5/8/2026
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
Reiterated RatingBuy$53.00
5/7/2026
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
UpgradeSell (D-)Sell (D)
5/7/2026
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
Boost Price TargetOutperform$128.00 ➝ $142.00
5/7/2026
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
Boost Price TargetBuy$125.00 ➝ $145.00
5/7/2026
Qiagen N.V. stock logo
QGEN
Qiagen
Reiterated RatingHold$46.00 ➝ $40.00
5/7/2026
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
Reiterated RatingStrong-Buy$165.00
5/7/2026
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
Set Price Target$185.00
5/7/2026
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
Reiterated RatingOutperform$138.00
5/7/2026
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
Set Price Target$136.00
5/7/2026
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
UpgradeModerate Buy
(Data available from 5/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
$39.21M172.63N/AN/A$18.72 per share4.40
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
$521.31M12.14$0.05 per share2,141.27$3.98 per share26.09
Qiagen N.V. stock logo
QGEN
Qiagen
$2.09B3.26$3.44 per share9.60$16.17 per share2.04
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
N/AN/AN/AN/A$9.86 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
-$311.35M-$3.57N/AN/AN/A-611.94%-24.71%-22.05%N/A
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
-$23.36M-$13.61N/A358.01N/A-140.24%-11.28%-3.84%7/30/2026 (Estimated)
Qiagen N.V. stock logo
QGEN
Qiagen
$424.88M$1.9117.2512.283.2519.16%14.40%8.40%N/A
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
-$111.48M-$2.60N/AN/AN/AN/A-24.78%-23.44%N/A

Latest RAPP, QGEN, KYMR, and MIRM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2026Q1 2026
Qiagen N.V. stock logo
QGEN
Qiagen
$0.54$0.54N/A$0.33$496.15 million$492.32 million
5/7/2026Q1 2026
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
-$0.56-$0.42+$0.14-$0.42$7.50 million$20.00 million
5/6/2026Q1 2026
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
-$0.75-$13.43-$12.68-$13.43$148.21 million$159.88 million
4/30/2026Q1 2026
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
-$0.89-$0.71+$0.18-$0.71$8.27 million$34.37 million
3/10/2026Q4 2025
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
-$0.65-$0.72-$0.07-$0.72N/AN/A
2/26/2026Q4 2025
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
-$0.77-$0.97-$0.20-$0.97$14.80 million$2.87 million
2/25/2026Q4 2025
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
$0.02-$0.11-$0.13-$0.12$141.78 million$148.93 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
N/AN/AN/AN/AN/A
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
N/AN/AN/AN/AN/A
Qiagen N.V. stock logo
QGEN
Qiagen
$0.260.79%N/A13.61%N/A
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
N/AN/AN/AN/AN/A

Latest RAPP, QGEN, KYMR, and MIRM Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/11/2026
Qiagen N.V. stock logo
QGEN
Qiagen
annual$0.351.04%7/7/20267/7/20267/14/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
N/A
10.81
10.81
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
1.28
2.09
1.99
Qiagen N.V. stock logo
QGEN
Qiagen
0.49
3.21
3.31
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
N/A
27.08
26.17

Institutional Ownership

CompanyInstitutional Ownership
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
N/A
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
N/A
Qiagen N.V. stock logo
QGEN
Qiagen
70.00%
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
N/A

Insider Ownership

CompanyInsider Ownership
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
15.98%
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
14.36%
Qiagen N.V. stock logo
QGEN
Qiagen
9.00%
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
13.57%
CompanyEmployeesShares OutstandingFree FloatOptionable
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
17082.26 million69.11 millionOptionable
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
14060.98 million52.22 millionOptionable
Qiagen N.V. stock logo
QGEN
Qiagen
5,654206.07 million187.53 millionOptionable
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
N/A47.83 million41.34 millionN/A

Recent News About These Companies

MISE A DISPOSITION DU RAPPORT FINANCIER ANNUEL 2025

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Kymera Therapeutics stock logo

Kymera Therapeutics NASDAQ:KYMR

$82.28 -2.22 (-2.62%)
As of 03:12 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Mirum Pharmaceuticals stock logo

Mirum Pharmaceuticals NASDAQ:MIRM

$103.82 -7.57 (-6.79%)
As of 03:13 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.

Qiagen stock logo

Qiagen NYSE:QGEN

$33.02 -0.27 (-0.81%)
As of 03:13 PM Eastern
This is a fair market value price provided by Massive. Learn more.

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.

Rapport Therapeutics stock logo

Rapport Therapeutics NASDAQ:RAPP

$37.35 -0.60 (-1.57%)
As of 03:13 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Rapport Therapeutics Inc. is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc. is based in BOSTON.